shakedown.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
A community for live music fans with roots in the jam scene. Shakedown Social is run by a team of volunteers (led by @clifff and @sethadam1) and funded by donations.

Administered by:

Server stats:

261
active users

#glp1

0 posts0 participants0 posts today

'The willpower involved is seen as admirable; the idea – which has been debunked by research into obesity – is that anyone can have a slim body, if they only try hard enough. By contrast, using injections to lose weight is perceived as easy, even “lazy"'. theguardian.com/lifeandstyle/2 #foodstudies #diet #obesity #GLP1 #satiety

The Guardian · ‘I lost so much weight, my husband thought I was terminally ill’: why do people lie about taking Ozempic?By Imogen West-Knights

Meghan Rosen: A shadowy market for weight-loss drugs has emerged online. Shortages and big price tags have driven patients to unconventional sources of GLP-1 drugs

"As of February 28, the FDA has received nearly 800 reports of adverse events linked to compounded semaglutide or tirzepatide. These reports aren’t proof of causation, but it’s possible some adverse events may be due to dosing errors. …"

1/2
#GLP1 #weightloss #health #pharmacy
sciencenews.org/article/weight

Science News · A shadowy market for weight-loss drugs has emerged onlinePeople are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.
Continued thread

Some patients in trials for the newest weight-loss drugs are losing ~too much~ weight, eating peanut butter and skipping doses to avoid losing more.

But that conflicts with the industry's hunger for ever-larger weight loss percentages. How are those two interests getting reconciled?

statnews.com/2025/02/20/too-mu

STAT · How much weight loss is too much? Pharma is pushing the limit with new obesity drugsHow much weight loss is too much? Pharma is pushing the limit with new obesity drugs.

Eye doctors at the University of Utah Health and elsewhere published the research, which describes several cases of vision complications possibly tied to these obesity and diabetes drugs. The medications were linked to three different eye conditions, all of which can lead to blindness. But as the doctors caution, the cases alone do not prove that GLP-1 drugs can cause these issues, and more research is needed to understand exactly what’s going on. #health #GLP1 gizmodo.com/eye-doctors-are-fi

Gizmodo · Eye Doctors Are Finding New Links Between Ozempic and Vision ProblemsA new case series links GLP-1 use to three different eye conditions, all of which can lead to blindness.
Continued thread

Sorry, #dulaglutide med #trulicity; the more general description of these drugs is #glp1 receptor agonists.

medscape.com/viewarticle/glp-1

Apparently various professional orgs have been kinda all over the map on whether or not to hold such meds pre-op, but now they are coalescing -- still without formal evidence-based guidance, mind you -- around 24-hour liquid diet in preoperative phase, especially for higher doses of the meds for patients on weekly regimens.

Medscape · GLP-1 RAs Safe in the Perioperative Period: New GuidanceBy Diana Swift

"Some of the benefits appeared to last, however, only as long as patients were taking the drug."

Eli Lilly Says Weight-Loss Drug Sharply Reduces Diabetes Progression

The drug also led to significant weight reduction

Weekly injections of Zepbound for more than 3 years reduced the risk of progression to Type 2 diabetes by 94%, compared with a placebo, among people with excess weight and prediabetes.

🎁🔗:
wsj.com/health/pharma/eli-lill

Continued thread

Your longread for today: how Mojsov (and many women) get pushed to the margins as history is written, even by close collaborators:

“It was because of Joel and I being friends and talking about science a lot, and me having so much respect for him as a scientist, and my underappreciating what she had done with peptides and not really tuned in that she had her own employment in the endocrine unit.”
statnews.com/2023/09/27/weight

STAT · The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she’s been edged out of the storySvetlana Mojsov, on the discovery of GLP-1: “This is not about me getting prizes. It’s about me actually not being erased from the scientific literature.”

Calling this trial "positive" simply doesn't do it justice.

This is an outrageously positive trial.

I've long been a proponent of #GLP1 as first line for DM. I'd say the same should probably be true for anyone with obesity and an obesity related condition (HTN/DM/HFpEF). I'm even more excited for the more potent agents to be trialed. Primary care is slowly going to evolve into a #GLP1 prescribing.

#MedMastodon

nejm.org/doi/full/10.1056/NEJM

“It’s one thing to reach out to physicians and say ‘We’ve got these treatments and they’re so effective and we want you to know about them,’ I don’t think that’s ever going to explain over 100 meals. You just have to laugh, it’s so crazy.”

by (who else but) @STAT's Nick Florko: statnews.com/2023/07/05/ozempi

STATNovo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like OzempicNovo Nordisk bought 457,222 meals to educate doctors about its drugs like Ozempic. More than 200 doctors had more than 50 meals with the company.
#obesity#drugs#GLP1